Boosting Female Sexual Response by RECONNECTing the Dots
- PMID: 31599837
- DOI: 10.1097/AOG.0000000000003534
Boosting Female Sexual Response by RECONNECTing the Dots
Comment on
-
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.Obstet Gynecol. 2019 Nov;134(5):899-908. doi: 10.1097/AOG.0000000000003500. Obstet Gynecol. 2019. PMID: 31599840 Free PMC article. Clinical Trial.
-
Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder.Obstet Gynecol. 2019 Nov;134(5):909-917. doi: 10.1097/AOG.0000000000003514. Obstet Gynecol. 2019. PMID: 31599847 Free PMC article.
References
-
- Bassoon R. Human sex response cycle. J Sex Marital Ther 2001;27:33–43.
-
- Clayton AH. Epidemiology and neurobiology of female sexual dysfunction. J Sex Med 2007;4(suppl 4):260–8.
-
- Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol 2019;134:899–908.
-
- Simon JA, Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol 2019;134:909–17.
-
- U.S. Food and Drug Administration. FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-new-tre.... Retrieved August 22, 2019.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical